An investigation on behalf of investors in Galectin Therapeutics Inc (NASDAQ:GALT) shares over potential wrongdoing at Galectin Therapeutics Inc was announced and NASDAQ:GALT stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/11/2018 -- An investigation was announced for investors in NASDAQ:GALT shares over potential breaches of fiduciary duties by certain officers.
Investors who purchased shares of Galectin Therapeutics Inc (NASDAQ:GALT) certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Galectin Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Berkeley Lake, GA based Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. Shares of Galectin Therapeutics Inc (NASDAQ:GALT) rose from $1.88 per share on December 19, 2017 to as high as $4.60 per share on January 10, 2018.
Those who purchased shares of Galectin Therapeutics Inc (NASDAQ:GALT), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego